Transcode Therapeutics (RNAZ) Current Assets (2020 - 2026)
Transcode Therapeutics' (RNAZ) quarterly Current Assets came in at $16.7 million in Q1 2026, up 28.4% YoY from $13.0 million in Q1 2025, and down 23.81% on a QoQ basis from $22.0 million in Q4 2025.
Transcode Therapeutics (RNAZ) Current Assets (2020 - 2026) Analysis & Trends
Transcode Therapeutics (RNAZ) has 7 years of Current Assets data on file, last reported at $16.7 million in Q1 2026.
- Quarterly Current Assets rose 28.4% year-over-year to $16.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $16.7 million (up 28.4% YoY) and the FY2025 annual result came in at $22.0 million, up 209.92% from the prior year.
- Current Assets slipped to $16.7 million in Q1 2026, from $22.0 million in the prior quarter.
- In the past five years, Current Assets ranged from a high of $22.0 million in Q4 2025 to a low of $3.6 million in Q3 2024.
- A 5-year average of $9.5 million and a median of $7.4 million in 2022 frame the typical range for Current Assets.
- Annual changes were most pronounced in 2022 — Current Assets surged 2476.88% — and 2023, when it plunged 76.67%.
- Tracing RNAZ's Current Assets over 5 years: stood at $7.4 million in 2022, then tumbled by 39.62% to $4.5 million in 2023, then jumped by 59.21% to $7.1 million in 2024, then jumped by 209.92% to $22.0 million in 2025, then dropped by 23.81% to $16.7 million in 2026.
- The last three Current Assets figures came in at $16.7 million (Q1 2026), $22.0 million (Q4 2025), and $4.8 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 12.54 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 18.45 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 8.07 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 5.82 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 7.22 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 4.62 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 18.80 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 1.63 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 1.76 Bn |
| 10 | Transcode Therapeutics | 2.84 Mn | 2.84 Mn | - | 10.64 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 16.75 Mn |
| Dec 31, 2025 | 21.98 Mn |
| Sep 30, 2025 | 4.75 Mn |
| Jun 30, 2025 | 8.24 Mn |
| Mar 31, 2025 | 13.04 Mn |
| Dec 31, 2024 | 7.09 Mn |
| Sep 30, 2024 | 3.61 Mn |
| Jun 30, 2024 | 4.39 Mn |
| Mar 31, 2024 | 6.71 Mn |
| Dec 31, 2023 | 4.46 Mn |
| Sep 30, 2023 | 9.37 Mn |
| Jun 30, 2023 | 4.89 Mn |
| Mar 31, 2023 | 4.35 Mn |
| Dec 31, 2022 | 7.38 Mn |
| Sep 30, 2022 | 11.57 Mn |
| Jun 30, 2022 | 13.92 Mn |
| Mar 31, 2022 | 18.63 Mn |
| Dec 31, 2021 | 22.73 Mn |
| Sep 30, 2021 | 25.20 Mn |
| Jun 30, 2021 | 540,219.00 |